Additionally, we employed cycloheximide (CHX) and MG132 treatments in nasopharyngeal carcinoma cells, and the results indicated that circCDYL2 did not impact the half-life or ubiquitin-mediated degradation of RAD51 (Supplemental Fig. 4C & D). Here, RAD51 is linked to nasopharyngeal carcinoma.